Bellicum Pharmacueticals Company Profile (NASDAQ:BLCM)

About Bellicum Pharmacueticals

Bellicum Pharmacueticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company's CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLCM
  • CUSIP:
Key Metrics:
  • Previous Close: $19.46
  • 50 Day Moving Average: $18.58
  • 200 Day Moving Average: $13.30
  • 52-Week Range: $7.24 - $23.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.26
  • P/E Growth: 0.00
  • Market Cap: $526.35M
  • Outstanding Shares: 27,048,000
  • Beta: 1.51
Profitability:
  • Net Margins: -21,774.65%
  • Return on Equity: -42.22%
  • Return on Assets: -38.29%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 16.36%
  • Quick Ratio: 16.36%
Additional Links:
Companies Related to Bellicum Pharmacueticals:

Analyst Ratings

Consensus Ratings for Bellicum Pharmacueticals (NASDAQ:BLCM) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.25 (25.32% upside)
Analysts' Ratings History for Bellicum Pharmacueticals (NASDAQ:BLCM)
Show:
DateFirmActionRatingPrice TargetDetails
8/23/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/9/2016Piper Jaffray Cos.Reiterated RatingOverweight$25.00 -> $31.00View Rating Details
8/9/2016Citigroup Inc.UpgradeNeutral -> Buy$24.00View Rating Details
6/2/2016SunTrust Banks Inc.Initiated CoverageBuy$20.00View Rating Details
9/11/2015GuggenheimUpgradeNeutral -> Buy$38.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Bellicum Pharmacueticals (NASDAQ:BLCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q216($0.57)($0.61)$0.06 millionViewListenView Earnings Details
5/9/2016($0.51)($0.44)ViewN/AView Earnings Details
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details
5/11/2015Q1($0.22)($0.30)$0.11 millionViewN/AView Earnings Details
3/11/2015Q4($11.79)($18.99)$0.02 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellicum Pharmacueticals (NASDAQ:BLCM)
Current Year EPS Consensus Estimate: $-2.34 EPS
Next Year EPS Consensus Estimate: $-2.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.50)($0.50)($0.50)
Q2 20162($0.60)($0.59)($0.60)
Q3 20162($0.64)($0.64)($0.64)
Q4 20162($0.65)($0.60)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellicum Pharmacueticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bellicum Pharmacueticals (NASDAQ:BLCM)
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 65.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Ken MoseleyVPSell11,800$20.10$237,180.00View SEC Filing  
9/23/2016Kevin M SlawinInsiderSell23,416$20.12$471,129.92View SEC Filing  
9/20/2016David M SpencerInsiderSell2,500$20.01$50,025.00View SEC Filing  
9/20/2016Ken MoseleyVPSell2,200$20.01$44,022.00View SEC Filing  
8/15/2016Ken MoseleyVPSell1,000$20.00$20,000.00View SEC Filing  
8/15/2016Kevin M SlawinInsiderSell67,000$19.31$1,293,770.00View SEC Filing  
7/27/2016David M. SpencerInsiderSell10,000$15.00$150,000.00View SEC Filing  
7/18/2016Kevin M SlawinCTOSell2,719$13.99$38,038.81View SEC Filing  
7/15/2016Kevin M SlawinCTOSell22,281$13.72$305,695.32View SEC Filing  
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.00View SEC Filing  
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00View SEC Filing  
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00View SEC Filing  
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00View SEC Filing  
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.00View SEC Filing  
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.00View SEC Filing  
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00View SEC Filing  
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.00View SEC Filing  
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bellicum Pharmacueticals (NASDAQ:BLCM)
DateHeadline
kcregister.com logoDon't Miss: Bellicum Pharmaceuticals (NASDAQ:BLCM), Concordia International Corp. (NASDAQ:CXRX), Oconee ... - KC Register (NASDAQ:BLCM)
www.kcregister.com - September 24 at 3:46 PM
News IconInsider Trading Activity in: Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) - The Voice Registrar (NASDAQ:BLCM)
voiceregistrar.com - September 24 at 8:06 AM
News IconShares Recorded Gapping Higher Pre-Market: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Post News (NASDAQ:BLCM)
www.kentuckypostnews.com - September 23 at 3:19 PM
streetinsider.com logoBellicum Pharma (BLCM) Presents Data from BPX-501 Trial at ESID Meeting - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - September 23 at 8:58 AM
biz.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Other Events (NASDAQ:BLCM)
biz.yahoo.com - September 23 at 8:58 AM
News IconBellicum To Present At The 2016 Healthcare Conference (NASDAQ:BLCM)
www.biospace.com - September 21 at 3:18 PM
marketwatch.com logoThis is no time for speculators to stay on the sidelines (NASDAQ:BLCM)
www.marketwatch.com - September 21 at 3:18 PM
News IconStock Perspective: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Company Earnings Watch - Frisco Fastball (NASDAQ:BLCM)
friscofastball.com - September 21 at 8:24 AM
finance.yahoo.com logoBellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference - Yahoo Finance (NASDAQ:BLCM)
finance.yahoo.com - September 21 at 8:24 AM
biz.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an (NASDAQ:BLCM)
biz.yahoo.com - September 21 at 8:24 AM
News IconSunTrust Weighs in on Bellicum Pharmaceuticals Inc's Q2 2016 Earnings (BLCM) - DailyQuint (NASDAQ:BLCM)
dailyquint.com - September 20 at 9:45 AM
News IconBellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference - Yahoo Sports (NASDAQ:BLCM)
sports.yahoo.com - September 20 at 9:45 AM
News IconBrokerages gives Consensus Recommendation of “Buy” to Bellicum ... - DailyQuint (NASDAQ:BLCM)
dailyquint.com - September 19 at 4:45 PM
News IconHow Many Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)'s Analysts Are Bullish? - Post News (NASDAQ:BLCM)
www.kentuckypostnews.com - September 17 at 3:49 PM
News IconExpert Analysts Perspective For: Bellicum Pharmaceuticals, Inc ... - Wall Street Times (press release) (NASDAQ:BLCM)
www.wallstreetnews24.com - September 15 at 8:47 PM
News IconAnalyst Watch-list: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , Loxo Oncology, Inc. (NASDAQ:LOXO) - Wall Street Times (press release) (NASDAQ:BLCM)
www.wallstreetnews24.com - September 12 at 8:38 AM
finance.yahoo.com logoBellicum Pharmaceuticals to Present at the BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference (NASDAQ:BLCM)
finance.yahoo.com - September 1 at 12:19 PM
kcregister.com logoHot News: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), Egalet Corporation (NASDAQ:EGLT), Ryder System, Inc ... - KC Register (NASDAQ:BLCM)
www.kcregister.com - August 23 at 9:06 PM
News IconJefferies Group Reiterates Buy at Bellicum Pharmacueticals Inc. (NASDAQ: BLCM) - BNB Daily (blog) (NASDAQ:BLCM)
www.baseball-news-blog.com - August 23 at 9:06 PM
nasdaq.com logoBellicum Pharmaceuticals (BLCM) is in Overbought Territory: What's Next? - Nasdaq (NASDAQ:BLCM)
www.nasdaq.com - August 17 at 3:58 PM
finance.yahoo.com logoBellicum Pharmaceuticals (BLCM) is in Overbought Territory: What's Next? (NASDAQ:BLCM)
finance.yahoo.com - August 17 at 12:04 PM
finance.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Financials (NASDAQ:BLCM)
finance.yahoo.com - August 16 at 3:59 PM
bizjournals.com logoBothell biotech Biolife Solutions posts record revenue on heels of new supply agreement - Puget Sound Business Journal (Seattle) (blog) (NASDAQ:BLCM)
www.bizjournals.com - August 16 at 12:35 PM
finance.yahoo.com logoEdited Transcript of BLCM earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:BLCM)
finance.yahoo.com - August 16 at 12:35 PM
bizjournals.com logoBothell biotech Biolife Solutions posts record revenue on heels of new supply agreement (NASDAQ:BLCM)
www.bizjournals.com - August 15 at 11:04 AM
seekingalpha.com logoBioLife inks 10-year supply deal with Bellicum Pharma - Seeking Alpha (NASDAQ:BLCM)
seekingalpha.com - August 12 at 3:21 PM
capitalcube.com logoETF’s with exposure to Bellicum Pharmaceuticals, Inc. : August 11, 2016 (NASDAQ:BLCM)
www.capitalcube.com - August 11 at 3:55 PM
capitalcube.com logoBellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:BLCM)
www.capitalcube.com - August 10 at 3:19 PM
streetinsider.com logoBioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM) Enter CryoStor Supply Agreement - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - August 10 at 7:16 AM
News IconBellicum Reports Second Quarter 2016 Financial Results And Provides Corporate Update (NASDAQ:BLCM)
www.biospace.com - August 9 at 4:59 PM
4-traders.com logoBellicum Pharmaceuticals : posts 2Q loss (NASDAQ:BLCM)
www.4-traders.com - August 9 at 12:46 PM
twst.com logoBellicum Pharmaceuticals Inc.: Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BLCM)
www.twst.com - August 9 at 12:46 PM
businesswire.com logoBellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update - Business Wire (press release) (NASDAQ:BLCM)
www.businesswire.com - August 8 at 9:17 PM
publicnow.com logoBellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BLCM)
www.publicnow.com - August 8 at 9:17 PM
biz.yahoo.com logoQ2 2016 Bellicum Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:BLCM)
biz.yahoo.com - August 8 at 8:40 AM
businesswire.com logoBellicum Announces BPX-501 European Regulatory Updates - Business Wire (press release) (NASDAQ:BLCM)
www.businesswire.com - August 4 at 9:37 PM
publicnow.com logoBellicum Announces BPX-501 European Regulatory Updates (NASDAQ:BLCM)
www.publicnow.com - August 4 at 9:37 PM
fool.com logoBetter Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics - Motley Fool (NASDAQ:BLCM)
www.fool.com - August 3 at 3:55 PM
finance.yahoo.com logoBellicum to Report Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 8, 2016 - Yahoo Finance (NASDAQ:BLCM)
finance.yahoo.com - August 2 at 3:55 PM
publicnow.com logoBellicum to Report Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 8, 2016 (NASDAQ:BLCM)
www.publicnow.com - August 1 at 7:21 AM
news.cmlviz.com logoBellicum Pharmaceuticals Inc (NASDAQ:BLCM) Stock Technicals Hit Strength - CML News (NASDAQ:BLCM)
news.cmlviz.com - July 22 at 12:03 PM
News IconHeightened Volatility Spotted on Shares of: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Engelwood Daily (NASDAQ:BLCM)
www.engelwooddaily.com - July 20 at 4:23 PM
streetinsider.com logoBellicum Pharma (BLCM) Announces Issuance of US Patent Covering CaspaCIDe Cell Therapy Method - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - July 20 at 4:23 PM
News IconShares Jumping Higher in Session: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - TGP (NASDAQ:BLCM)
telanaganapress.com - July 20 at 4:23 PM
capitalcube.com logoETF’s with exposure to Bellicum Pharmaceuticals, Inc. : July 19, 2016 (NASDAQ:BLCM)
www.capitalcube.com - July 19 at 12:04 PM
News IconWere Analysts Bullish Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) This Week? - Consumer Eagle (NASDAQ:BLCM)
www.consumereagle.com - July 17 at 8:34 AM
News IconBellicum Pharmaceuticals Inc on Focus After Crashing In Today's Session - Press Telegraph (NASDAQ:BLCM)
presstelegraph.com - July 14 at 12:43 PM
News IconBellicum Pharmaceuticals Incorporated (NASDAQ:BLCM) Shorts Decreased by 0.5% After Short Covering - Press Telegraph (NASDAQ:BLCM)
presstelegraph.com - July 13 at 3:51 PM
News IconShare Volatility Watch for: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Engelwood Daily (NASDAQ:BLCM)
www.engelwooddaily.com - July 13 at 3:51 PM
News IconStock Volatility Focus for: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Engelwood Daily (NASDAQ:BLCM)
www.engelwooddaily.com - July 11 at 3:50 PM

Social

Bellicum Pharmacueticals (NASDAQ:BLCM) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff